EFFECTS OF BERAPROST SODIUM COMBINED WITH CALCIUM DOBESILATE ON SERUM T-PA, PAI-1, LKN-1, TNF-Α AND IL-33 IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS

Yu Zong

Department of Internal Medicine, The 5th People's Hospital of Jinan, Jinan, PR China

Aim: To investigate the effect of beraprost sodium combined with calcium dobesilate on serum tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), leukocyte-induced hormone-1 (LKN-1), tumour necrosis factor alpha (TNF-α), and interleukin 33 (IL-33) in patients with chronic glomerulonephritis. 

Methods: Eighty-six patients with chronic glomerulonephritis admitted to our hospital from March 2017 to March 2018 were enrolled in the control group and treatment group. The control group was treated with calcium dobesilate, while in the treatment group, 43 patients were treated with beraprost sodium combined with calcium dobesilate. The two groups were treated continuously for two months and the clinical efficacy, adverse reactions, serum levels of t-PA, PAI-1, LKN-1, TNF-α and IL-33 were observed in the two groups. 

Results: The total effective rate of the control group and the treatment group were 79.07% and 93.02%, respectively. The total effective rate of the control group was significantly lower than that of the treatment group, while the difference between the two groups was statistically significant (P<0.05). After treatment, the t-PA activity of the two groups was higher than that before treatment, while the PAI-1 activity was significantly lower than that before treatment (P<0.05). The t-PA activity of the treatment group was significantly higher than that of the control group, and the PAI-1 activity was significantly lower than that of the control group, with statistically significant differences (P<0.05). After treatment, the levels of serum LKN-1, TNF-α and IL-33 in the two groups were significantly lower than those before treatment (P<0.05), while the serum LKN-1, TNF-α and L-33 were also significantly lower than that of the control group. Furthermore, the difference was statistically significant (P<0.05). There were two cases of nausea and vomiting and two cases of headache and dizziness in the treatment group, while the incidence rate was 9.30%. Additionally, the control group showed one case of nausea and vomiting and two cases of headache and dizziness, while the incidence rate was 6.98%. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 

Conclusion: Beraprost sodium combined with calcium dobesilate has an obvious therapeutic effect on chronic glomerulonephritis, which can effectively increase the activity of t-PA, decrease the activity of PAI-1, and regulate the level of LKN-1, TNF-α and IL-33. Moreover, it significantly improves the renal function of patients, is safe and reliable, and is worthy of promotion.